Bioequivalence study of a generic quetiapine in healthy male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 9, 2008, Pages 489-496

  Mahatthanatrakul, Wera ^a   Rattana, K ^a   Sriwiriyajan, S ^a   Wongnawa, M ^a   Ridtitid, W ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Bioequivalence; Pharmacokinetics; Quantia 200 ; Quetiapine; Seroquel

Indexed keywords

QUANTIA 200; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

EID: 52149090989     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46489     Document Type: Article

References (17)

1. AstraZeneca. Product monograph: Seroquel® 2006.
2. Center for Drug Evaluation and Research (CDER). Guidance for Industry Bioanalytical Method Validation, US-FDA. 2001; 4-10.
3. Crismon ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC et al. (eds). Pharmacotherapy - a pathophysiologic approach. 5th ed. New York: McGraw-Hill; 2002. p. 1219-1223.
4. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. J Clin Pharmacokinetics. 2001; 40: 509-522.
5. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. J Psychopharmacol (Berl). 1998; 135: 119-126.
6. Goren JL, Levin GM. Quetiapine, an atypical antipsychotic. J Pharmacother. 1998; 18: 1183-1194.
7. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interaction for Seroquel. J Schizophrenia Res. 1997; 24: 198.
8. Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interaction. J Drug Metabol Drug Interactions. 2006; 21: 187-211.
9. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ. Applied therapeutics: The clinical use of drugs. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 76.
10. Li KY, Li X, Cheng ZN, Peng WX, Zhang BK, Li HD. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. J Acta Pharmacologica Sinica. 2004; 25: 390-394.
11. Mandrioli R, Fanali S, Ferranti A, Raggi MA. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J Pharmaceut Biomed Analysis. 2002; 30: 969-977.
12. Rahi M, Heikkinen T, Hartter S et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol. 2007; 26: 45-50.
13. Sadock BJ, Sadock VA. Pocket handbook of psychiatric drug treatment. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 206.
14. Saracino MA, Mercolini L, Flotta G, Albers LJ, Merli R, Raggi MA. Simultaneous determination of fluvoxamine isomers and quetiapine in human plasma by means of high-performance liquid chromatography. J Chromatograph B. 2006; 843: 227-233.
15. Schatzberg AF, Nemeroff CR. Essential of clinical psychopharmacology. Washington DC: American Psychiatry Publishing; 2001. p.145-150.
16. Thai Food and Drug Administration (FDA). Criteria and guideline for the bioequivalence study of generic drug; 2006.
17. Wrighton SA, Thummel KE. CYP3A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds). Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 230-252.